基因表达与通路网络整合分析框架GenPath-PPH利用持久路径同调（PPH）检测疾病相关通路拓扑结构动态变化，在肝细胞癌PBMC样本中成功识别JAK-STAT、NF-κB等已知通路及氨基酸tRNA合成等潜在新靶点，通过方向性约束网络过滤噪声，结合Kolmogorov-Smirnov检验和Cohen效应量 ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognized GenPath Diagnostics, a business unit of BioReference Laboratories, Inc ...

Kenneth Weg, former vice chairman of Bristol-Myers Squibb, first heard the details about a technology to prioritize the best drug targets about a year ago. Raju Kucherlapati, a fellow member of the ...

Cambridge-based GenPath Pharmaceuticals Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (“BRLI”) (NASDAQ: BRLI) announced today that it has completed an equity investment in InCellDx, Inc. (“InCellDx”), a privately ...

GenPath Pharmaceuticals Inc., Cambridge, Mass., raised $15.5 million in a Series A financing. The round was led by MPM Capital and joined by Venrock Associates, Prospect Venture Partners, Greylock and ...

Bio-Reference Laboratories, Inc. has announced that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the ...

Little more than a year after starting a business based on spontaneous tumor models in mice, GenPath Pharmaceuticals Inc. raised $42.7 million in a Series B financing. (BioWorld Today) ...

GenPath Pharmaceuticals Inc., Cambridge, Mass., raised $42.7 million in series B funding. Flagship Ventures led the round, which included Highland Capital Partners, Oxford Biosciences, existing ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...

ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...

Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, ...